ACute and Chronic Effects of Saxagliptin

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Glucose ACCES study will explore the acute and long term (12-week treatment) effects of saxagliptin in patients with impaired glucose tolerance during fasting and after a standardised breakfast. The investigations will be performed on:

• glycemic parameters

• on cardiovascular parameters

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Saxagliptin

Criteria

Inclusion Criteria:

• Social security affiliation

• Persons without TUTORSHIP that can freely agree to participate to the study

• Age between 18 to 70 years

• Impaired glucose tolerance diagnosed during the previous month.

Exclusion criteria:

• Pregnancy

• Breast feeding

• Diabetes

• No contraception

• Body Mass Index > 45 kg/m²

• Arterial blood pressure > 160/110 mmHg

• Creatinine clearance < 60 ml/min

• Severe hepatocellular insufficiency

• Chronic respiratory disease

• Anaemia (Hemoglobin < 10 g/dl)

• Peripheral arterial occlusive disease

• Heart failure

• Cardiac arrhythmia